A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy

• Published in: Breast cancer (Tokyo, Japan) Japan), 2023-01, Vol.30 (1), p.131-138
• Main Authors: Ohsumi, Shozo, Nishimura, Reiki, Masuda, Norikazu, Akashi-Tanaka, Sadako, Suemasu, Kimito, Yamauchi, Hideko, Tokunaga, Eriko, Ikeda, Tadashi, Nishi, Tsunehiro, Hayashi, Hiroto, Iino, Yuichi, Takatsuka, Yuichi, Ohashi, Yasuo, Inaji, Hideo
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Breast cancer; Breast Neoplasms - radiotherapy; Breast Neoplasms - surgery; Cancer; Cancer Research; Care and treatment; Chemotherapy; Diseases; Female; Health aspects; Hormones; Humans; Mastectomy, Segmental; Medicine; Medicine & Public Health; Methods; Neoplasm Recurrence, Local - epidemiology; Neoplasm Recurrence, Local - prevention & control; Oncology; Original; Original Article; Prospective Studies; Radiotherapy; Radiotherapy, Adjuvant; Relapse; Surgery; Surgical Oncology; Tamoxifen; Women
• ISSN: 1340-6868; 1880-4233
• DOI: 10.1007/s12282-022-01406-5

Background Breast-conserving surgery with radiotherapy is one of standard treatments for early breast cancer. However, it is regarded as an option to treat elderly patients with small hormone receptor-positive breast cancer with breast-conserving surgery and hormone therapy without radiotherapy. We conducted two sequential prospective studies to examine the feasibility of breast-conserving surgery without radiotherapy since 2002 and present the results. Patients and methods Primary female breast cancer patients who fulfilled the strict eligibility criteria were prospectively enrolled in two sequential studies named WORTH 1 and 2. The surgical materials were sliced in 5-mm intervals and all slices were examined microscopically. Postoperative radiotherapy was not allowed, but tamoxifen or anastrozole was administered for 5 years. Ipsilateral breast tumor recurrence (IBTR)-free survival was the primary outcome. Results The data of the two studies were combined ( N  = 321). The median follow-up period for IBTR was 94 months (4–192 months). Only three patients were treated with adjuvant chemotherapy. The 5- and 10-year IBTR-free rates were 97.0% and 90.5%, respectively. The age at operation and PR status affected IBTR rates independently. When we calculated IBTR-free rates of patients who were 65 years of age or older at the time of surgery and had PR-positive tumors, the 5- and 10-year IBTR rates were both 98.4%. Conclusions  Our “5-mm-thick slice and 5-mm free-margin” method may be effective to select patients who can be treated by breast-conserving surgery and hormone therapy without radiotherapy.